Top 10 Later Stage Lead Investors: Biotechnology/LifeSciences
| Rank | Investor Name |
|---|---|
| 1 | RA Capital Management |
| 2 | ARCH Venture Partners |
| 3 | Forbion Capital Partners |
| 4 | Nextech Invest |
| 5 | Column Group |
| 6 | SR One Capital Management |
| 7 | Dimension |
| 8 | Illumina Ventures |
| 9 | Sanofi Ventures |
| 10 | Ally Bridge Group |
Clinical data readouts and large pharma acquisition appetite set the pace of investment across biotech, with capital concentrating in firms that can underwrite science. These firms are ranked by rounds led rather than participation, so this is the short list of investors actually pricing later stage deals in the category.
The CapitalDart directory identifies the right person to contact at each of these firms, with their individual investment criteria.
Rankings reflect investment activity from January 2025 through July 2026 in US and Canada companies, based on transactions matched to the CapitalDart directory. Seed and Early Stage rank by participation, Later Stage by rounds led, Private Equity by control and buyout activity. Updated periodically.